ArticleBMC complementary medicine and therapies2025
Integration of network pharmacology and molecular docking reveals the anti-inflammatory efficacy of formononetin in Huangqin decoction and experiment verification in DSS-induced zebrafish IBD model.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated multi-omics maps how processed black ginseng modulates gut homeostasis through rare ginsenosides.NPJ science of food · 2026Article
- Zebrafish as a translational platform for investigating multi-organ pharmacological interactions of traditional Chinese medicine.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe Huangqin decoction (HQD) is widely used in clinical practice and has significant therapeutic effects on inflammatory bowel disease (IBD). However, its active ingredients and mechanisms of action for IBD remain unknown.
objectiveThis study aimed to elucidate the underlying mechanism of HQD through network pharmacology and molecular docking and to verify the effectiveness of the potential active components by preliminary experimental verification.
methodsThe principal components and related protein targets of HQD were retrieved through TCMSP and Uniprot database. The disease targets were obtained in GeneCards database. The intersection targets of drug and disease were imported into STRING 11.5 database to construct the protein-protein interaction (PPI) network. GO enrichment analysis and KEGG pathway enrichment analysis of intersection targets were performed using Metascape platform. AutoDock1.5.7 software was used to verify the molecular docking between core components and core targets. The DSS-induced zebrafish IBD model was used to approve the effects of selected core targets formononetin.
resultsA total of 170 active components, 192 related targets and 43 intersection targets of IBD were obtained, including 6 core components and 9 core targets. 1090 results were obtained from GO analysis, including 1001, 31 and 58 results from biological process (BP), cellular component (CC), and molecular function (MF) respectively. Enrichment analysis of the KEGG pathway yielded 139 results. The results of molecular docking confirmed that HQD could exert synergistic effects through multi-components, multi-targets and multi-pathways. Furthermore, formononetin has been demonstrated as a beneficial component through molecule docking screening, which effectively affected dextran sulfate sodium (DSS)-induced zebrafish intestinal increasing neutrophils numbers, changed zebrafish larvae intestine morphology, and provided new ideas and new methods for further research on the mechanism of HQD or corresponding active targets screening in the treatment of IBD.
conclusionThis study comprehensively illustrates the bioactive, potential targets, and molecular mechanism of HQD against IBD. It also provided a promising strategy to uncover the scientific basis and therapeutic mechanism of traditional Chinese medicine formulae in treating IBD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.